Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012
Phase 1
Completed
- Conditions
- HypertensionHyperlipidemias
- Interventions
- Drug: AD-2011 10/20 mgDrug: AD-2012 80mgDrug: AD-2011 10/20 mg + AD-2012 80mg
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03586037
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath